KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

AbbVie (ABBV) Debt to Equity (2016 - 2025)

AbbVie (ABBV) has disclosed Debt to Equity for 14 consecutive years, with -$24.99 as the latest value for Q3 2025.

  • On a quarterly basis, Debt to Equity fell 313.46% to -$24.99 in Q3 2025 year-over-year; TTM through Sep 2025 was -$24.99, a 313.46% decrease, with the full-year FY2024 number at $20.19, up 253.55% from a year prior.
  • Debt to Equity was -$24.99 for Q3 2025 at AbbVie, down from $45.23 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $45.23 in Q1 2025 to a low of -$24.99 in Q3 2025.
  • A 5-year average of $7.22 and a median of $5.21 in 2021 define the central range for Debt to Equity.
  • Biggest YoY gain for Debt to Equity was 391.81% in 2025; the steepest drop was 313.46% in 2025.
  • AbbVie's Debt to Equity stood at $4.16 in 2021, then decreased by 17.75% to $3.42 in 2022, then surged by 66.97% to $5.71 in 2023, then skyrocketed by 253.55% to $20.19 in 2024, then plummeted by 223.76% to -$24.99 in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Debt to Equity are -$24.99 (Q3 2025), $45.23 (Q1 2025), and $20.19 (Q4 2024).